LAURA DROKE: Open Payments
NPI 1861025173 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 54 payments from 9 companies in 2025. Trend: 2023 $557 · 2024 $1,044 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 27 | $328 |
| PFIZER INC. | 16 | $207 |
| Abbott Laboratories | 2 | $165 |
| CVRx, Inc. | 3 | $88 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Novo Nordisk Inc | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
Products named: LEQVIO, VYNDAQEL, ESPRIT, Barostim Neo System, ELIQUIS, ENTRESTO, Wegovy, UPTRAVI.
Industry payments across AR — which companies pay providers there.
